Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice

Abstract Background Therapeutic approaches aimed at lowering toxic mutant huntingtin (mHTT) levels in the brain can reverse disease phenotypes in animal models of Huntington's disease (HD) and are currently being evaluated in clinical trials. Sensitive and dynamic response biomarkers are needed to a...

Повний опис

Бібліографічні деталі

Автори:	Nicholas S. Caron, Lauren M. Byrne, Fanny L. Lemarié, Jeffrey N. Bone, Amirah E.-E. Aly, Seunghyun Ko, Christine Anderson, Lorenzo L. Casal, Austin M. Hill, David J. Hawellek, Peter McColgan, Edward J. Wild, Blair R. Leavitt, Michael R. Hayden
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-10-01
Серія:	Translational Neurodegeneration
Предмети:	Neurofilament light chain Response biomarker Huntington's disease Huntingtin lowering Antisense oligonucleotide Cerebrospinal fluid
Онлайн доступ:	https://doi.org/10.1186/s40035-024-00443-8
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!